Image: Biontech
It was 9.4 billion euros net, after 10.3 billion euros in the previous year. Sales fell from 19 to 17.3 billion euros.
In 2021, the Mainz-based company and the US partner company Pfizer delivered more than 2.6 billion corona vaccine doses, compared to two billion last year.
In view of the declining revenue from the corona vaccine, Biontech now wants to advance the development of therapies against cancer, for example. For future oncology products, the group wants to set up a sales organization in the USA, the EU and other regions this year and in 2024.
A total of 2.4 to 2.6 billion euros are to be invested in research and development this year. Another part of the profit is to flow into a share buyback program of up to 0.5 billion euros.
more from economy
